- Home
- PRTS vs BTAI Comparison
PRTS vs BTAI Comparison
Compare PRTS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTS | BTAI |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 35.6M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PRTS | BTAI |
|---|---|---|
| Price | $0.82 | $1.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $0.50 | ★ $25.33 |
| AVG Volume (30 Days) | ★ 987.0K | 952.6K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $1.17 |
| 52 Week High | $1.36 | $8.08 |
Technical Indicators
Market Signals| Indicator | PRTS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 46.32 |
| Support Level | $0.70 | $1.50 |
| Resistance Level | $0.93 | $2.18 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 70.70 | 30.26 |
Price Performance
Historical ComparisonAbout PRTS CarParts.com Inc.
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.